Screener
Bio-Rad Laboratories BIO Trading Securities in Marketable Securities
Trading Securities in Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The source filing: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 4:19 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000012208-26-000035
Included in Other investments in the condensed consolidated balance sheet are investments without readily determinable fair value measured at cost with adjustments for observable price changes or impairments. The carrying value of these investments was $23.7 million and $23.0 million as of March 31, 2026 and December 31, 2025, respectively.
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bio-Rad Laboratories's trading securities in marketable securities?
- Bio-Rad Laboratories (BIO) reported trading securities in marketable securities of $23.7M in Q1 2026.
- How has Bio-Rad Laboratories's trading securities in marketable securities changed year-over-year?
- Bio-Rad Laboratories's trading securities in marketable securities increased by 3.0% year-over-year, from $23M to $23.7M.
- What is the long-term trend for Bio-Rad Laboratories's trading securities in marketable securities?
- Over 2 years (2020 to 2025), Bio-Rad Laboratories's trading securities in marketable securities has grown at a 578.2% compound annual growth rate (CAGR), from $500K to $23M.
Ask your AI about Bio-Rad Laboratories's trading securities in marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude